Eyepoint Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2025: 51.43%

Eyepoint Pharmaceuticals Inc (EYPT) has an Asset Resilience Ratio of 51.43% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Eyepoint Pharmaceuticals Inc (EYPT) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$129.44 Million

Cash + Short-term Investments

Total Assets

$251.69 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2024)

This chart shows how Eyepoint Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See Eyepoint Pharmaceuticals Inc (EYPT) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Eyepoint Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Eyepoint Pharmaceuticals Inc (EYPT) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$129.44 Million	51.43%
Total Liquid Assets	$129.44 Million	51.43%

Asset Resilience Insights

Very High Liquidity: Eyepoint Pharmaceuticals Inc maintains exceptional liquid asset reserves at 51.43% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Eyepoint Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Eyepoint Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Eyepoint Pharmaceuticals Inc (2009–2024)

The table below shows the annual Asset Resilience Ratio data for Eyepoint Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	64.81%	$271.21 Million	$418.46 Million	+50.79pp
2023-12-31	14.02%	$49.79 Million	$355.18 Million	-13.11pp
2022-12-31	27.13%	$48.93 Million	$180.36 Million	+14.61pp
2021-12-31	12.52%	$32.97 Million	$263.37 Million	--
2020-12-31	0.00%	$0.00	$91.72 Million	--
2017-12-31	0.00%	$0.00	$18.68 Million	--
2016-12-31	43.26%	$13.68 Million	$31.62 Million	+14.18pp
2015-12-31	29.09%	$9.41 Million	$32.37 Million	+16.10pp
2014-12-31	12.99%	$2.94 Million	$22.67 Million	-7.78pp
2013-12-31	20.76%	$3.37 Million	$16.25 Million	-27.52pp
2012-12-31	48.29%	$9.95 Million	$20.60 Million	+24.48pp
2011-12-31	23.81%	$11.22 Million	$47.11 Million	+19.04pp
2010-12-31	4.77%	$2.05 Million	$43.01 Million	-0.76pp
2009-12-31	5.53%	$2.05 Million	$37.10 Million	--

pp = percentage points

About Eyepoint Pharmaceuticals Inc

NASDAQ:EYPT USA Biotechnology

Market Cap

$1.09 Billion

Market Cap Rank

#8705 Global

#2427 in USA

Share Price

$13.15

Change (1 day)

+2.10%

52-Week Range

$8.28 - $18.85

All Time High

$48.20